A Phase II Study of Ibrutinib in Patients with Persistent or Recurrent Marginal Zone Lymphoma

Full Title
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma

Ibrutinib is a drug for patients with previously treated chronic lymphocytic leukemia or mantle cell lymphoma. In this study, researchers want to assess the safety and effectiveness of ibrutinib in patients with marginal zone lymphoma that has continued to grow or has come back despite prior therapy.

Ibrutinib works by blocking a protein inside lymphoma cells called Bruton’s tyrosine kinase (BTK), which helps lymphoma cells to live and grow. It is a capsule that is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have marginal zone lymphoma that has continued to grow or has come back despite prior therapy that included a drug targeting the CD20 protein (such as rituximab).
  • At least 3 weeks must have passed between completion of previous therapy and entry into the study (70 days for radio-immunotherapies).
  • Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ariela Noy at 212-639-7423.

Lymphoma: Non-Hodgkin's Lymphoma
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »